Belinostat
| CAS No. | 866323-14-0 | Cat. No. | BCP24610 |
| Name | Belinostat | ||
| Synonyms | PXD 101; PXD101; PXD-101; PX105684; PX-105684; PX 105684; | ||
| Formula | C15H14N2O4S | M. Wt | 318.37 |
| Description | Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. Belinostat was approved in 2014 for relapsed or refractory peripheral T-cell lymphoma. | ||
| Pathways | Cell Cycle/DNA Damage Epigenetics | ||
| Targets | HDAC | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.